APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT03997383

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03997383
  • EudraCT 2019-001458-24
Other papers using this trial's data
  • Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis The New England journal of medicine, 2023-10-26 DOI, PubMed 37888916, PMC10757426 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis Arquivos brasileiros de cardiologia, 2025-03 DOI, PubMed 40243852, PMC12107767 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, Czechia, Denmark, France, Hong Kong SAR China, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Portugal, South Korea, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03997383. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-04 (actual); primary completion 2022-06-20 (actual). Results posted on 2023-10-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Condition
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intervention (Drug)
Placebo
Intervention (Drug)
Patisiran
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03997383
Content hash
5f89025ef6c76d17f05e886f5f9a4484db12015ddb667d5f6ad1dc3e2f06b182